Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 9, 2005, Pages 728-734

  Priviero, Fernanda B M ^a   Baracat, Juliana S ^a   Teixeira, Cleber E ^a   Claudino, Mário A ^a   De Nucci, Gilberto ^a   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

1H 1,2,4 oxadiazolo 4,3 a quinoxalin 1 one; Aorta; BAY 41 2272; Nitric oxide; Sildenafil; Soluble guanylate cyclase

Indexed keywords

(5 CYCLOPROPYL 2 [1 (2 FLUORO BENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] PYRIMIDIN 4 YLAMINE); 1H [1,2,4]OXADAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCHOLINE; GUANYLATE CYCLASE ACTIVATOR; GUANYLATE CYCLASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENOBARBITAL; SILDENAFIL; UNCLASSIFIED DRUG; 1H (1,2,3)OXADIAZOLO(4,4 A)QUINOXALIN 1 ONE; 1H-(1,2,3)OXADIAZOLO(4,4-A)QUINOXALIN-1-ONE; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO(3,4 B)PYRIDINE; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; GUANYLATE CYCLASE; OXADIAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; NONHUMAN; RABBIT; STATISTICAL ANALYSIS; VASODILATATION; ANIMAL; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; IN VITRO STUDY; MALE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GUANYLATE CYCLASE; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; OXADIAZOLES; PIPERAZINES; PYRAZOLES; PYRIDINES; QUINOXALINES; RABBITS; SIGNAL TRANSDUCTION; VASODILATION;

EID: 26944451367     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04262.x     Document Type: Article

References (41)

1. Moncada S, Rees DD, Schulz R et al. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl Acad. Sci. USA 1991; 88: 2166-70.
2. Ignarro LJ, Bush PA, Buga GM et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. 1990; 170: 843-50.
3. Lucas KA, Pitari GM, Kazerounian S et al. Guanylate cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000; 52: 375-414.
4. Hofmann F, Ammendola A, Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. J. Cell Sci. 2000; 113: 1671-6.
5. Juilfs DM, Soderling S, Burns F et al. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev. Physiol. Biochem. Pharmacol. 1999; 135: 67-104.
6. Hobbs FD. The new British Hypertension Society guidelines: A view from primary care. J. Hum. Hypertens. 2000; 14: 223-5.
7. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch. Pharmacol. 1998; 358: 113-22.
8. Ko FN, Wu CC, Kuo SC et al. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994; 84: 4226-33.
9. Wu CC, Ko FN, Kuo SC et al. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. 1995; 116: 1973-8.
10. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylate cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996; 15: 6863-8.
11. Mulsch A, Bauersachs J, Schafer A et al. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylate cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 1997; 120: 681-9.
12. Hoenicka M, Becker EM, Apeler H et al. Purified soluble guanylate cyclase expressed in a baculovirus/Sf9 system: Stimulation by YC-1, nitric oxide, and carbon monoxide. J. Mol. Med. 1999; 77: 14-23.
13. Stasch JP, Becker EM, Alonso-Alija C et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001; 410: 212-15.
14. Becker EM, Alonso-Alija C, Apeler H et al. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol. 2001; 1: 13-24.
15. Straub A, Stasch JP, Alonso-Alija C et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. 2001; 11: 781-4.
16. Boerrigter G, Costello-Boerrigter LC, Cataliotti A et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003; 107: 686-9.
17. Galle J, Zabel U, Hubner U et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 1999; 127: 195-203.
18. Stasch JP, Schmidt P, Alonso-Alija C et al. NO- and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. 2002; 136: 773-83.
19. Wohlfart P, Malinski T, Ruetten H et al. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylate cyclase. Br. J. Pharmacol. 1999; 128: 1316-22.
20. Baracat JS, Teixeira CE, Okuyama CE et al. Relaxing effects induced by the soluble guanylate cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur. J. Pharmacol. 2003; 477: 163-9.
21. Garthwaite J, Southam E, Boulton CL et al. Potent and selective inhibition of nitric oxide-sensitive guanylate cyclase by 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 1995; 48: 184-8.
22. Schrammel A, Behrends S, Schmidt K et al. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylate cyclase. Mol. Pharmacol. 1996; 50: 1-5.
23. Thomazzi SM, Moreira J, De Nucci G et al. Inhibitory effects of human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase. Biochem. Pharmacol. 2005; 69: 875-82.
24. Brunner F, Schmidt K, Nielsen EB. et al. Novel guanylate cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J. Pharmacol. Exp. Ther. 1996; 277: 48-53.
25. Javid PJ, Watts SW, Webb RC. Inhibition of nitric oxide-induced vasodilation by gap junction inhibitors: A potential role for a cGMP-independent nitric oxide pathway. J. Vasc. Res. 1996; 33: 395-404.
26. Bolotina VM, Najibi S, Palacino JJ et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 2003; 368: 850-3.
27. Yousif MH, Oriowo MA, Williams KI. Sodium nitroprusside-induced cGMP-independent vasodilator responses in the perfused rabbit ovarian vascular bed. Pharmacol. Res. 1998; 38: 381-6.
28. Yu M, Sun CW, Maier KG et al. Mechanism of cGMP contribution to the vasodilator response to NO in rat middle cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 2002; 282: H1724-31.
29. 2+ uptake activity can account for the reduced response to NO, but not sodium nitroprusside, in hypercholesterolemic rabbit orta. Circulation 2001; 104: 1040-5.
30. Mingone CJ, Gupte SA, Iesaki T et al. Hypoxia enhances a cGMP-independent nitric oxide relaxing mechanism in pulmonary arteries. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003; 285: L296-304.
31. Hwang TL, Hung HW, Kao SH et al. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol. Pharmacol. 2003; 64: 1419-27.
32. 2 analogues elicit vascular relaxation: Cyclic AMP-independent, Gs-protein mediated-activation of MaxiK channel. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2004; 2: 257-65.
33. Ercan ZS, Turker RK. The relaxing activity of iloprost and prostaglandin E2 in the isolated various smooth muscle strips of the rabbit. Pharmacology 1985; 31: 61-6.
34. Demirel E, Turker RK. Inhibition of iloprost of the contractile effect of noradrenaline in mesenteric artery rings: Evidence for a possible calcium-dependent mechanism. Prostaglandins Leukot. Essent. Fatty Acids 1991; 42: 185-9.
35. Sparwasser C, Drescher P, Will JA et al. Smooth muscle tone regulation in rabbit cavernosal and spongiosal tissue by cyclic AMP- and cyclic GMP-dependent mechanisms. J. Urol. 1994; 152: 2159-63.
36. 1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE4). J. Urol. 1999; 162: 1848-55.
37. 2+ entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. Biochem. Pharmacol. 2001; 62: 679-84.
38. Wallis RM, Corbin JD, Francis SH et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. 1999; 83 (Suppl. 5A): C3-12.
39. Ferrer M, Encabo A, Conde MV et al. Heterogeneity of endothelium- dependent mechanisms in different rabbit arteries. J. Vasc. Res. 1995; 32: 339-46.
40. Chen Y, Traverse JH, Hou M et al. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 2003; 284: H1513-20.
41. Dishy V, Sofowora G, Harris PA et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin. Pharmacol. Ther. 2001; 70: 270-9.